A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional)).

Trial Profile

A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional)).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors LIDDS
  • Most Recent Events

    • 09 Nov 2017 According to a LIDDS media release, recruitment rate of patients has increased as more trial centers have been included in the plan.
    • 31 Aug 2017 According to a LIDDS media release, the Canadian Medicines Agency has approved the study protocol for this clinical study. Screening of patients have been completed and the first patients have been treated.
    • 09 Jun 2017 Planned End Date changed from 30 Jun 2019 to 30 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top